Literature DB >> 12941804

Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.

Leah C Pulling1, Kevin K Divine, Donna M Klinge, Frank D Gilliland, Terri Kang, Ann G Schwartz, Therese J Bocklage, Steven A Belinsky.   

Abstract

Adenocarcinoma (AC) is the most common type of lung cancer diagnosed in the United States, comprising up to 40% of tumors in smokers and 50-80% of tumors in never-smokers. Exposures to cigarette smoke, direct or second-hand, and radiation in the form of radon progeny are the major risk factors for lung AC in both smokers and never-smokers. The goal of the current study was to determine the prevalence for O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in a large sample of central or peripheral ACs from smokers (n = 157), former uranium miners (n = 34), and never-smokers (n = 46). The mutation rate at codon 12 of the K-ras gene was determined to assess whether activation of this oncogene was associated with MGMT methylation. The overall prevalence for MGMT methylation was 51%. Significantly more tumors from never-smokers than smokers exhibited MGMT methylation (66 versus 47%, respectively). In contrast, exposure to radon through uranium mining did not affect the prevalence for methylation. The frequency of MGMT methylation was increased significantly in association with tumor stage. K-ras mutations were detected in 24% of all ACs and 22, 24, and 28% of tumors from never-smokers, smokers, and miners, respectively. Alterations in both the K-ras and MGMT genes were seen in only 11% of ACs. Kaplan-Meier survival estimates did not reveal any difference between patient survival with or without MGMT methylation. In contrast, survival was significantly reduced over the initial 60 months after diagnosis for patients with a transition mutation in the K-ras gene compared with those with a transversion mutation. This investigation demonstrates that MGMT promoter hypermethylation is a common event in the progression of early stage AC of the lung. We have shown that the incidence of MGMT methylation was significantly higher in never-smokers than smokers and have detected a higher frequency of mutations within the K-ras gene than previously reported in never-smokers. This study also suggests that K-ras activation is independent of MGMT methylation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941804

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.

Authors:  Masanori Fujii; Nobukazu Fujimoto; Akio Hiraki; Kenichi Gemba; Keisuke Aoe; Shigeki Umemura; Hideki Katayama; Nagio Takigawa; Katsuyuki Kiura; Mitsune Tanimoto; Takumi Kishimoto
Journal:  Cancer Sci       Date:  2012-01-13       Impact factor: 6.716

2.  Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.

Authors:  Robert A Meguid; Craig M Hooker; James Harris; Li Xu; William H Westra; J Timothy Sherwood; Marc Sussman; Stephen M Cattaneo; James Shin; Solange Cox; Joani Christensen; Yelena Prints; Nance Yuan; Jennifer Zhang; Stephen C Yang; Malcolm V Brock
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

Review 3.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

Review 4.  Second-hand smoke and human lung cancer.

Authors:  Ahmad Besaratinia; Gerd P Pfeifer
Journal:  Lancet Oncol       Date:  2008-07       Impact factor: 41.316

5.  Role of loss of o⁶-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression.

Authors:  Na-Hye Myong
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

6.  DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.

Authors:  Ivo Teneng; Maria A Picchi; Shuguang Leng; Christopher P Dagucon; Suresh Ramalingam; Carmen S Tellez; Steven A Belinsky
Journal:  DNA Repair (Amst)       Date:  2019-04-27

Review 7.  Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis.

Authors:  Chao Chen; Haiqing Hua; Chenglong Han; Yuan Cheng; Yin Cheng; Zhen Wang; Jutao Bao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients.

Authors:  Yang Liu; Qing Lan; Jill M Siegfried; James D Luketich; Phouthone Keohavong
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

9.  Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy.

Authors:  Mingqing Tang; William Xu; Qizhao Wang; Weidong Xiao; Ruian Xu
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

10.  DNA hypermethylation of tumor-related genes in gastric carcinoma.

Authors:  Su Hyung Hong; Ho Gak Kim; Woon Bok Chung; Eun Young Kim; Jong Young Lee; Sang Mo Yoon; Joong Goo Kwon; Yoon Kyung Sohn; Eun Kyung Kwak; Jung Wan Kim
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.